Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Prior Notice Of Board Meeting In Terms Of Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 ,inter alia, to consider and approve Notice is hereby given pursuant to Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the meeting of the Board of Directors of Fredun Pharmaceuticals Limited is scheduled to be held on Wednesday, 24th May, 2023 at 04.00 p.m. at inter alia, to consider and approve the following: 1. Consider and approve Audited Financial Results for the quarter and financial year ended March 31, 2023 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date. 2. Consider and recommend final dividend on the paid-up equity shares for the Financial Year ended March 31, 2023.
18-05-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Allotment Of 47,850 Equity Shares To Non-Promoters Upon Conversion Of Warrants Into Equity Shares

 This is to inform you that Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2023, has done allotment of convertible warrants on Preferential Basis to Non-Promoters on May 2, 2023. Further, we would like to inform that the Warrant Holders have paid the balance of the consideration aggregating to Rs. 2,38,34,085/- and have applied for exercising their rights for conversion of 47,850 warrants into equivalent number of Equity Shares. Consequently, the Board of Directors in its meeting held today i.e. May 02, 2023 has allotted 47,850 Equity Shares of face value Rs. 10/- each to the warrant holders.
02-05-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Statement Of Deviation Or Variation In The Use Of Proceeds Of Preferential Issue

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds, from the objects stated in in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated September 22, 2021. A statement confirming that there is no deviation or variation in the utilisation of these proceeds for quarter ended December 31, 2021, duly reviewed by the Audit Committee is attached.
28-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Statement Of Deviation Or Variation In The Use Of Proceeds Of Preferential Issue

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds, from the objects stated in in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated September 22, 2021. A statement confirming that there is no deviation or variation in the utilisation of these proceeds for quarter ended September 30, 2022, duly reviewed by the Audit Committee is attached
28-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Statement Of Deviation Or Variation In The Use Of Proceeds Of Preferential Issue

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds, from the objects stated in in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated August 27, 2022. A statement confirming that there is no deviation or variation in the utilisation of these proceeds for quarter ended December 31, 2022, duly reviewed by the Audit Committee is attached.
28-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Statement Of Deviation Or Variation In The Use Of Proceeds Of Preferential Issue.

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds, from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated August 27, 2022. A statement confirming that there is no deviation or variation in the utilisation of these proceeds for quarter ended March 31, 2023, duly reviewed by the Audit Committee is attached.
21-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Yearly Certificate Under Regulations 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 40(9) of SEBI Listing Regulations, 2015, ('LODR') we enclose herewith a Certificate for the year ended March 31, 2023 of Fredun Pharmaceuticals Limited duly issued by Ms. Kala Agarwal, Practising Company Secretary.
21-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Yearly Certificate Under Regulations 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 40(9) of SEBI Listing Regulations, 2015, ('LODR') we enclose herewith a Certificate for the year ended March 31, 2023 of Fredun Pharmaceuticals Limited duly issued by Ms. Kala Agarwal, Practising Company Secretary.
21-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement Under Regulation 30-Submission Of RPT For The Half Year Ended 31.03.2021

 Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit the details of Related Party Transactions entered for the half year ended 31st March 2021 . The relevant provisions of Regulation 15 of SEBI (LODR) Regulations, 2015 are applicable to the Company from F.Y 2022-23; however, as directed by the good office of BSE Limited, we are submitting the Related Party Transaction Report for the above-mentioned period.
06-04-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement Under Regulation 30-Submission Of RPT For The Half Year Ended 30.09.2020

 Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit the details of Related Party Transactions entered for the half year ended 30th September, 2020. The relevant provisions of Regulation 15 of SEBI (LODR) Regulations, 2015 are applicable to the Company from F.Y 2022-23; however, as directed by the good office of BSE Limited, we are submitting the Related Party Transaction Report for the above-mentioned period.
06-04-2023
Next Page
Close

Let's Open Free Demat Account